NASDAQ:ALGS

Aligos Therapeutics Q2 2025 Earnings Results & Report

Aligos Therapeutics logo
$1.66 -0.44 (-20.95%)
Closing price 04:00 PM Eastern
Extended Trading
$1.68 +0.03 (+1.51%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aligos Therapeutics beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 6, 2025. The company reported EPS of -$1.53 versus the -$2.35 consensus estimate, while revenue of $965 thousand topped the $433 thousand estimate by $532 thousand.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Aligos Therapeutics EPS Results

Actual EPS
-$1.53
Consensus EPS
-$2.35
Beat/Miss
Beat by +$0.82
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Aligos Therapeutics Revenue Results

Actual Revenue
$965 thousand
Expected Revenue
$433 thousand
Beat/Miss
Beat by +$532.00 thousand
YoY Revenue Growth
N/A

Aligos Therapeutics Q2 2025 Earnings FAQ

Aligos Therapeutics (NASDAQ:ALGS) reported earnings of -$1.53 per share for Q2 2025, beating the consensus estimate of -$2.35. The report was announced on Wednesday, August 6, 2025.

Aligos Therapeutics reported revenue of $965 thousand for Q2 2025, against a consensus estimate of $433 thousand.

Aligos Therapeutics Earnings Headlines

Aligos Therapeutics (NASDAQ:ALGS) Rating Lowered to Sell at Wall Street Zen
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Aligos Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aligos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aligos Therapeutics and other key companies, straight to your email.

About Aligos Therapeutics

Aligos Therapeutics (NASDAQ:ALGS) is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2018, it focuses on developing medicines for viral infections and liver diseases.

The company’s research has included investigational treatments for chronic hepatitis B and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Its development work has involved small-molecule drug candidates, including approaches intended to interfere with viral replication.

Aligos is focused on research and clinical development rather than marketing approved medicines. Its programs are investigational, and their development status may change as clinical testing and company priorities evolve.

View Aligos Therapeutics Profile